FDA Brief

Warning letters Drugs

FDA warning letter to

24HrDoc, Inc. dba 24HrDoc

MediumIssued Feb 20Posted Mar 3Center for Drug Evaluation and Research (CDER)

FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.

What happened

FDA reviewed the website https://www.24hrdoc.com in December 2025 and found it offers compounded semaglutide and tirzepatide drug products. The product labels pictured on the site show the name "24HrDoc," which suggests 24HrDoc is the compounder of those drugs when it is not. The site also states "Same ingredients as: Ozempic and Wegovy" and "Same ingredients as: Mounjaro and Zepbound," which imply the compounded products were FDA-approved or evaluated for safety and effectiveness when they were not.

What FDA found

  1. The pictured labels carry the 24HrDoc name, which tells buyers 24HrDoc made the drug when it did not.

    FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR 201.1(h)(2)
  2. Claiming the products have the same ingredients as Ozempic and Wegovy suggests FDA approval that compounded drugs do not have.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. Claiming the products have the same ingredients as Mounjaro and Zepbound suggests FDA approval that compounded drugs do not have.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  4. Sending misbranded drugs across state lines is a prohibited act.

    FDCA § 301(a) [21 U.S.C. § 331(a)]
  5. Receiving misbranded drugs in interstate commerce and delivering them is also prohibited.

    FDCA § 301(c) [21 U.S.C. § 331(c)]

What FDA wants

Within 15 working days, send the Office of Compounding Quality and Compliance a written response describing the steps taken to fix the violations and prevent them from recurring. FDA specifically asks the company to identify who makes the compounded products, supply sample labeling, and address or remove the misleading website claims.

Who should pay attention

  • telehealth platforms that sell compounded semaglutide and tirzepatide
  • compounding pharmacies whose products are marketed on third-party websites
  • marketing and compliance staff who write prescription drug website copy

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low